Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes

• Published in: Nutrition, metabolism, and cardiovascular diseases metabolism, and cardiovascular diseases, 2021-07, Vol.31 (8), p.2345-2353
• Main Authors: Sasso, Ferdinando Carlo, Pafundi, Pia Clara, Caturano, Alfredo, Galiero, Raffaele, Vetrano, Erica, Nevola, Riccardo, Petta, Salvatore, Fracanzani, Anna Ludovica, Coppola, Carmine, Di Marco, Vito, Solano, Antonio, Lombardi, Rosa, Giordano, Mauro, Craxi, Antonio, Perrella, Alessandro, Sardu, Celestino, Marfella, Raffaele, Salvatore, Teresa, Adinolfi, Luigi Elio, Rinaldi, Luca
• Format: Article
• Language: English
• Subjects: Cardiovascular risk; Direct acting antivirals; Hepatitis C virus; Prediabetes
• ISSN: 0939-4753; 1590-3729
• DOI: 10.1016/j.numecd.2021.04.016

Beyond type 2 diabetes, even a condition of prediabetes is associated with an increased cardiovascular (CV) risk, and HCV infection coexistence represents an exacerbating factor. CV prognosis improvement in prediabetes represents a challenge, due to the increasing prevalence of this metabolic condition worldwide. Hence, we aimed to prospectively assess how direct acting antivirals (DAAs) could affect major cardiovascular events (MACE) in a prediabetic HCV positive cohort. In this prospective multicenter study, we enrolled HCV patients with overt prediabetes. We compared a subgroup of patients treated with DAAs with untreated prediabetic controls. We recorded all CV events occurred during an overall median follow-up of 24 months (IQR 19–34). 770 HCV positive prediabetic patients were enrolled, 398 untreated controls and 372 DAAs treated patients. Overall, the CV events annual incidence was much higher among prediabetic treated patients (1.77 vs. 0.62, p